Webpackaging logo

Schreiner MediPharm and Sanofi develop innovative labeling solution for blinding syringes during clinical study trials

  • Schreiner MediPharm
Europe, Health, Primary Packaging, Secondary Packaging, Plastic, Flexible Materials

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 60 years, has developed – in close cooperation with the Clinical Trial Supplies Unit of Sanofi in Montpellier, France – an innovative solution for blinding syringes during clinical study trials.

To best guarantee valid and compliant results during clinical trials, it is important to neutralize investigational products to ensure that active drug and placebo cannot be distinguished from one another. At the same time, there is a legal obligation to provide extensive product information in different languages for drugs being tested. This presents a particular challenge for labeling, especially when transparent containers with small radii are involved.

For use in clinical trials, the label must provide sufficient space for compulsory text. In addition, it must ensure that each investigational product has the same appearance, even in transparent syringe barrels. Depending on the required amount of text, a one- or two-layered wrap design – each of which allows double-sided printing per layer of film – is used for the syringe. Accomplishing this requires extensive, high opacity printing of the transparent material.

The innovative product solutions that have been developed are based on a particularly long, one-layered wrap-around label named Pharma-Wrap, and a two-layered label, the so-called Euro-Label. Very flexible film material is required so that the label can be easily wrapped around the syringe with a small radius. The part of the label directly glued to the syringe consists of a tinted transparent film, enabling reliable neutralization of the syringe without obstructing content viewing. The remaining part of the label is printed on a white background, so that product information can be provided on both sides. The integrated peel-open tab enables easy opening and closing of the label.

These new specialty labels increase flexibility, efficiency, and safety for the execution of clinical trials, because one single label variant can be used globally for marking the respective product, while blinding it at the same time.

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Innovation
  • English
  • Modified 06 Jun 2016
  • Hits 1444